<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151326">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01873989</url>
  </required_header>
  <id_info>
    <org_study_id>1105008492</org_study_id>
    <nct_id>NCT01873989</nct_id>
  </id_info>
  <brief_title>Testosterone Replacement for Male Opioid Agonist Maintained Patients</brief_title>
  <official_title>Testosterone Replacement for Male Opioid Agonist Maintained Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to develop an effective treatment intervention for chronic pain,
      symptomatic hypogonadism, and opioid addiction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess the initial efficacy of testosterone replacement in male opioid
      agonist patients with symptomatic hypogonadism and chronic pain.

      The study has two specific aims:

        1. To estimate, in male opioid agonist maintained patients, the prevalence of
           (a)symptomatic hypogonadism and (b) co-occurring symptomatic hypogonadism and chronic
           pain.

        2. To conduct a pilot randomized clinical trial to obtain data regarding the feasibility,
           acceptability, and efficacy (compared to waitlist control) of testosterone replacement
           for male patients with POD and symptomatic hypogonadism treated with opioid agonist
           maintenance treatment (N=40).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduced illicit substance use</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduced illicit substance use will be assessed by urine toxicology and self-report.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain reduction will be assessed by self-report ratings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decreased sexual dysfunction</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decreased sexual dysfunction will be assessed on self-report measures.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Opioid Addiction</condition>
  <condition>Symptomatic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone replacement for hypogonadism.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm involves watchful waiting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone replacement</intervention_name>
    <arm_group_label>Testosterone replacement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Waitlist control</intervention_name>
    <arm_group_label>Waitlist control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 50 years of age

          -  Male buprenorphine- or methadone-maintained patients at the APT Foundation

          -  Moderate to severe chronic pain

          -  Meet criteria for symptomatic hypogonadism

          -  Understand English

          -  Interested in receiving testosterone replacement

        Exclusion Criteria:

          -  Current suicide or homicide risk

          -  Life-threatening or unstable medical condition

          -  Known or suspected prostate or chest cancer or history of polycythemia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher J Cutter, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Declan T Barry, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Declan T Barry, Ph.D.</last_name>
    <phone>203-285-2708</phone>
    <email>declan.barry@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Schottenfeld, M.D.</last_name>
    <phone>203-974-7349</phone>
    <email>richard.schottenfeld@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MRU, APT Foundation, Inc</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher J Cutter, Ph.D.</last_name>
      <phone>203-285-2717</phone>
      <email>christopher.cutter@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Declan T Barry, Ph.D.</last_name>
      <phone>203-285-2708</phone>
      <email>declan.barry@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher J Cutter, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Declan Barry</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Opioid addiction</keyword>
  <keyword>Symptomatic hypogonadism</keyword>
  <keyword>Testosterone replacement</keyword>
  <keyword>Opioid agonist maintenance</keyword>
  <keyword>Methadone</keyword>
  <keyword>Buprenorphine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
